Former Mylan Executive Faces Jail After Pleading Guilty To Insider Trading
Dayakar Mallu To Forfeit $4.27m Gained From Series Of Tips
Executive Summary
A six-year Mylan employee, Dayakar Mallu, is facing up to six years in jail after pleading guilty to insider trading and tax offence charges.
You may also be interested in...
Pfizer To Merge Off-Patent Business With Mylan
Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.
Mylan Spooks Investors With Surprise Plans For Higher 2019 Spending
Investors sold shares in Mylan after its management unexpectedly announced that it would increase sales and marketing expenses significantly in 2019 to boost growth of complex products that are now a much bigger portion of the generic and specialty drugmaker's revenue.
Mylan Gears Up To Launch US Advair Rival This Month
Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.